Evelo Biosciences

Evelo Biosciences company information, Employees & Contact Information

Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer. Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

Company Details

Employees
19
Founded
-
Address
One Kendall Square, Building 600/700,
Phone
+1 617 577 0300
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cambridge, MA
Looking for a particular Evelo Biosciences employee's phone or email?

Evelo Biosciences Questions

News

Evelo Bio Shutdown Follows a Series of Microbiome Therapy Trial Failures - MedCity News

Evelo Bio Shutdown Follows a Series of Microbiome Therapy Trial Failures MedCity News

Evelo Biosciences Announces $50 Million Series B Financing and Expansion of Board and Leadership Team - PR Newswire

Evelo Biosciences Announces $50 Million Series B Financing and Expansion of Board and Leadership Team PR Newswire

Evelo Biosciences Appoints Mark Plinio as Chief Commercial Officer - citybiz

Evelo Biosciences Appoints Mark Plinio as Chief Commercial Officer citybiz

Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients | Newswise - Newswise

Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients | Newswise Newswise

Developing Novel Therapy EDP1815 | Abdul Latif Jameel® - Abdul Latif Jameel

Developing Novel Therapy EDP1815 | Abdul Latif Jameel® Abdul Latif Jameel

Top Evelo Biosciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant